Curated News
By: NewsRamp Editorial Staff
July 30, 2026
Onco-Innovations Closes CAD$5M Private Placement for Cancer Programs
TLDR
- Onco-Innovations secured CAD$5M funding with warrants at $0.77, offering potential upside for investors.
- The funding uses an 18-month sharing arrangement based on share price, with monthly settlements for ONC010 development.
- Onco-Innovations advances cancer treatment with its ONC010 program and SynoGraph platform, aiming to improve patient outcomes.
- Onco-Innovations targets solid tumors with patented technology, and the funding includes a unique market-based settlement mechanism.
Impact - Why it Matters
This funding enables Onco-Innovations to advance its ONC010 program and SynoGraph(TM) platform, potentially accelerating the development of novel cancer treatments. For investors, the unique sharing arrangement offers exposure to the company's growth while mitigating risk. For patients, this could mean faster access to innovative therapies targeting solid tumours, addressing a critical need in oncology. The collaboration with Sorbie also signals confidence in Onco-Innovations' technology and strategy.
Summary
Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) has successfully closed a significant non-brokered private placement with Sorbie Bornholm LP and Sorbie Investments LLP, securing a notional subscription amount of approximately CAD$5 million. The financing involved the issuance of 7.94 million units at a notional price of CAD$0.63 per unit, each unit comprising one common share and one warrant exercisable at CAD$0.77 for three years. The proceeds will be made available through an innovative 18-month sharing arrangement tied to the volume-weighted average trading price of its shares, with monthly settlement amounts varying based on market performance. This unique structure provides Onco-Innovations with flexible access to capital while aligning investor returns with the company's stock performance.
The company plans to utilize the net proceeds to advance its ONC010 program, which includes manufacturing and preclinical activities, and to support the continued development of its SynoGraph(TM) platform. Additionally, funds will be allocated for working capital and general corporate purposes. Onco-Innovations is a Canadian-based oncology-focused company dedicated to cancer research and treatment, with an exclusive worldwide license to patented technology targeting solid tumours. This financing marks a pivotal step in accelerating its pipeline and bringing innovative cancer therapies closer to clinical trials.
As highlighted in the news release, the company’s progress is being monitored by investors through its newsroom at https://ibn.fm/ONNVF. BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio @ IBN, distributed this news, underscoring the importance of effective communication in the biotech sector. For more details, the full press release is available at https://ibn.fm/1Hrlg.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Onco-Innovations Closes CAD$5M Private Placement for Cancer Programs
